Banner

ISTA acquires rights to 3 ophthalmic compounds

Article

Irvine, CA-ISTA Pharmaceuticals, Irvine, CA, entered into an agreement with AcSentient Inc. under which ISTA will acquire rights to three late-stage ophthalmology compounds.

Related Videos
Related Content

Novartis finalizes divestment of ‘front of eye’ ophthalmology assets

September 30th 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

September 28th 2023

Novartis finalizes divestment of ‘front of eye’ ophthalmology assets

September 30th 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

September 28th 2023

Novartis finalizes divestment of ‘front of eye’ ophthalmology assets

September 30th 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

September 28th 2023
© 2023 MJH Life Sciences

All rights reserved.